⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256507 | 0.83 | SLC9A1 (0.35) | — | |
| SCHEMBL30614556 | 0.78 | — | — | |
| SCHEMBL16644635 | 0.78 | — | — | |
| SCHEMBL21223626 | 0.78 | — | — | |
| SCHEMBL6984571 | 0.74 | — | — | |
| SCHEMBL22530144 | 0.74 | — | — | |
| SCHEMBL21047964 | 0.74 | — | — | |
| SCHEMBL29963824 | 0.74 | — | — | |
| SCHEMBL16908269 | 0.74 | — | — | |
| SCHEMBL17187244 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025243046-A1 | COMPOUNDS | Pheno Therapeutics Limited (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4558498-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119698416-A | Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors | 英特莱治疗公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20100280010-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-11-04 | — | — | US | disclosed |
| EP-1984376-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1984376-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007087549-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |